Reinventing yourself is tough, especially when you're doing it at breakneck speed. That's the story unfolding at So-Young International Inc. (SY), which has spent the past two years transforming from an online platform connecting beauty seekers with cosmetic surgery providers into the operator of China's largest chain of "light" medical aesthetic clinics. The company's latest quarterly results, released last week, reveal a business caught between two worlds—one rapidly growing, the other fading fast.

The New Model Takes Shape

So-Young opened its first self-operated clinic at its Beijing headquarters in August 2023. Fast forward to today, and the company operates 42 such centers (one franchised), according to founder and chairman Jin Xing. That makes So-Young China's largest light medical aesthetic clinic chain, putting it on track to hit its target of 50 centers by year-end.

Jin isn't thinking small here. His long-term vision calls for 1,000 centers across China within eight to 10 years. Through the end of September, these clinics had already logged 600,000 cumulative service visits.

"Going forward, we will continue to expand our aesthetic center network in a disciplined manner and drive healthy, sustainable growth through a higher standard system and deeper brand equity," Jin said in the company's earnings release.

The transformation is moving fast, but it's expensive. As So-Young builds its brick-and-mortar presence, its original business—an online community and platform for people interested in cosmetic procedures and products—is evaporating.

The Numbers Tell a Split Story

Investors seem intrigued by the transformation narrative, but they're far from sold. So-Young's shares more than tripled from the beginning of the year through mid-July, hitting a multiyear high. But after the latest earnings announcement, the stock dropped 23% in just four days and has given back about half its gains from that July peak.

The quarterly numbers explain the hesitation. Aesthetic services from the new clinics brought in 183.6 million yuan in Q3, up a stunning 305% year-over-year. That's the good news. The other side of the ledger shows why investors got nervous: revenue from information and reservation services tied to the legacy platform fell 34.5% to 117.2 million yuan. Sales of medical products and maintenance services also dropped 25% to 67 million yuan.

Overall, So-Young posted total revenue of 386.7 million yuan for the quarter, up just 4% from 371.8 million yuan a year earlier. Nearly half now comes from the clinic operations—a remarkable shift in just two years.

But here's the painful part: as the company accelerated clinic openings, it swung to a net loss of 64.3 million yuan in Q3 from a profit of 20.3 million yuan a year earlier. Cash fell by roughly a quarter, from 1.25 billion yuan at the end of 2024 to 943 million yuan at the end of the third quarter. That's what happens when you're rapidly scaling a capital-intensive business.

How We Got Here

Understanding where So-Young is going requires looking at where it came from. When the company went public in 2019, it was an e-commerce platform connecting some 6,000 medical service providers across 300 cities with more than 1 million active users. People could search for cosmetic procedures, read reviews, and book appointments.

Founded in 2013 as an online community for cosmetic surgery information, So-Young added e-commerce capabilities in 2014 by partnering with medical aesthetic hospitals and clinics. Those providers became a primary revenue source, using the platform for advertising and bookings. So-Young earned commissions on transactions.

The company also sold cosmetic injectables like Botox and hyaluronic acid early on. Jin's personal connection to the industry runs deep—his mother is a plastic surgeon, and he openly shared his own experiences with face-slimming shots, hair transplants and injectable hyaluronic acid on the So-Young app. Jin started the company to make it easier for Chinese consumers to find reliable information about cosmetic surgery and related products as the economy boomed and demand exploded.

In 2021, So-Young acquired Wuhan Miracle, a medical products manufacturer serving hospitals. Revenue from both third-party injectables and Wuhan Miracle products has become a significant separate revenue stream since 2023.

The Contradiction at the Core

Here's where things get awkward. So-Young's current business structure creates an inherent conflict: the independent practitioners who pay for referrals from the platform now find themselves competing against So-Young's own clinics. That's an obvious long-term problem. Why would independent providers want to work with someone who's become a direct competitor?

On the flip side, operating its own clinics gives So-Young much tighter quality control compared to working with third parties. That matters in an industry plagued by small-scale clinics offering questionable service—a major target of regulatory crackdowns in recent years.

"As we increase store density and bring prices closer to those in Korea, I believe more and more consumers will choose to receive these treatments domestically," Jin told Bloomberg recently. He pointed to So-Young's mass procurement strategy and low marketing costs (thanks to strong brand recognition) as key advantages that let the company keep prices competitive.

The Market Opportunity

China's medical aesthetics market offers serious growth potential. Despite its size, penetration rates remain lower than South Korea, the U.S., Brazil and Japan. A recent KPMG report projects the market will quadruple from 311.5 billion yuan in 2023 to 1.3 trillion yuan by 2030. Non-surgical cosmetology—So-Young's specialty—accounts for about 38% of the market.

The demographics look favorable too. Among people new to cosmetic treatments last year, 56.9% were between 21 and 30 years old, with another 22% falling between 25 and 31.

New Competition Ahead

The shift from online services means So-Young no longer needs to compete with China's internet giants offering similar booking platforms. But the company now faces different rivals in the brick-and-mortar space, including Lancy Co. (002612.SZ), which recently acquired the prominent Beijing LiDu hospital and is partnering with Pumen, a medical aesthetics company, to develop new products.

Even after its big gains this year, So-Young's price-to-sales ratio of 1.45 trails slightly behind Lancy's 1.59.

The Verdict

Saying goodbye to a legacy business model isn't necessarily bad, and investors seem cautiously optimistic about So-Young's direction given the stock's strong performance this year. But the transition from a platform business to capital-intensive physical locations will likely bring more bumps along the way. The question is whether So-Young can reach profitability at scale before running through too much cash—or whether the growing clinic revenue will eventually compensate for the declining platform business.

For now, the company is caught in an uncomfortable middle ground, posting modest overall revenue growth while bleeding red ink. The transformation story is compelling, but it's still being written.